AP2015008441A0 - Pyrimido [4,5-B]quinoline-4,5(3H,10H)-diones as nonsense mutation suppressors - Google Patents

Pyrimido [4,5-B]quinoline-4,5(3H,10H)-diones as nonsense mutation suppressors

Info

Publication number
AP2015008441A0
AP2015008441A0 AP2015008441A AP2015008441A AP2015008441A0 AP 2015008441 A0 AP2015008441 A0 AP 2015008441A0 AP 2015008441 A AP2015008441 A AP 2015008441A AP 2015008441 A AP2015008441 A AP 2015008441A AP 2015008441 A0 AP2015008441 A0 AP 2015008441A0
Authority
AP
ARIPO
Prior art keywords
pyrimido
diones
quinoline
nonsense mutation
mutation suppressors
Prior art date
Application number
AP2015008441A
Other languages
English (en)
Inventor
Carsten Spanka
Niko Schmiedeberg
Juergen Reinhardt
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50030361&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP2015008441(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AP2015008441A0 publication Critical patent/AP2015008441A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Inorganic Chemistry (AREA)
  • Plural Heterocyclic Compounds (AREA)
AP2015008441A 2012-12-13 2013-12-12 Pyrimido [4,5-B]quinoline-4,5(3H,10H)-diones as nonsense mutation suppressors AP2015008441A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261736748P 2012-12-13 2012-12-13
PCT/IB2013/060859 WO2014091446A1 (en) 2012-12-13 2013-12-12 Pyrimido [4,5-b]quinoline-4,5 (3h,10h)-diones as nonsense mutation suppressors

Publications (1)

Publication Number Publication Date
AP2015008441A0 true AP2015008441A0 (en) 2015-05-31

Family

ID=50030361

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2015008441A AP2015008441A0 (en) 2012-12-13 2013-12-12 Pyrimido [4,5-B]quinoline-4,5(3H,10H)-diones as nonsense mutation suppressors

Country Status (24)

Country Link
US (2) US9649314B2 (h)
EP (1) EP2931282B1 (h)
JP (1) JP6076498B2 (h)
KR (1) KR101760586B1 (h)
CN (2) CN107569487A (h)
AP (1) AP2015008441A0 (h)
AU (1) AU2013358591B2 (h)
BR (1) BR112015013535A2 (h)
CA (1) CA2890692A1 (h)
CL (1) CL2015001610A1 (h)
CR (1) CR20150314A (h)
CU (1) CU20150061A7 (h)
EA (1) EA028673B1 (h)
ES (1) ES2709034T3 (h)
HK (1) HK1209637A1 (h)
IL (1) IL239244A0 (h)
IN (1) IN2015DN03998A (h)
MA (1) MA38157A1 (h)
MX (1) MX363437B (h)
PE (1) PE20151062A1 (h)
PH (1) PH12015501216A1 (h)
SG (1) SG11201503684WA (h)
TN (1) TN2015000262A1 (h)
WO (1) WO2014091446A1 (h)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP2015008441A0 (en) 2012-12-13 2015-05-31 Novartis Ag Pyrimido [4,5-B]quinoline-4,5(3H,10H)-diones as nonsense mutation suppressors
WO2015186062A1 (en) * 2014-06-03 2015-12-10 Novartis Ag PYRIMIDO[4,5-b]QUINOLINE-4,5(3H,10H)-DIONE DERIVATIVES
ES2743183T3 (es) * 2014-06-03 2020-02-18 Novartis Ag Derivados de piridopirimidinodiona como supresores de mutaciones finalizadoras
CU24438B1 (es) 2014-06-03 2019-09-04 Novartis Ag Compuestos derivados de 1,6 naftiridina-diona activos como supresores de mutación sin sentido
CN109152747A (zh) * 2016-04-15 2019-01-04 Uab研究基金会 用于刺激提前终止密码子的通读的方法和化合物
EP3762383B1 (en) * 2018-03-06 2023-12-06 The United States of America, as represented by the Secretary, Department of Health and Human Services Positive allosteric modulators of dopamine 1 receptor and method of use thereof
WO2019225625A1 (ja) * 2018-05-23 2019-11-28 京都薬品工業株式会社 リードスルー誘導剤およびその医薬用途
JP2023541601A (ja) 2020-09-10 2023-10-03 プレシリックス・ナームローゼ・ベンノートシヤープ Ｆａｐに対する抗体フラグメント
CA3208313A1 (en) 2021-01-13 2022-07-21 Monte Rosa Therapeutics Ag Isoindolinone compounds
WO2023203135A1 (en) 2022-04-22 2023-10-26 Precirix N.V. Improved radiolabelled antibody
WO2023213801A1 (en) 2022-05-02 2023-11-09 Precirix N.V. Pre-targeting
WO2024194607A1 (en) 2023-03-17 2024-09-26 Tay Therapeutics Limited Pyrimido[4,5-b][1,5]naphthyridine-4,5(3h,10h)-dione derivatives for the treatment of diseases associated with ptc mutations, such as e.g. cancer

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2884170B2 (ja) * 1989-08-24 1999-04-19 株式会社フジモト・ブラザーズ ５−デアザフラビン系化合物を有効成分とする制癌剤
WO1996028444A1 (en) 1995-03-15 1996-09-19 Pfizer Inc. 5,10-DIHYDROPYRIMIDO[4,5-b]QUINOLIN-4(1H)-ONE TYROSINE KINASE INHIBITORS
US6468990B1 (en) 1999-05-17 2002-10-22 Queen's University At Kingston Method of inhibiting binding of nerve growth factor to p75 NTR receptor
AU2003249244A1 (en) 2002-07-15 2004-02-02 Combinatorx, Incorporated Methods for the treatment of neoplasms
EP1631260A2 (en) 2003-02-28 2006-03-08 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
HUE055056T2 (hu) 2003-04-11 2021-10-28 Ptc Therapeutics Inc 1,2,4-oxadiazol-benzoesav vegyület és alkalmazása nonszensz szupresszióra és betegség kezelésére
PT2390255T (pt) 2006-04-03 2016-10-24 Technion Res & Dev Foundation Novos aminoglicosídeos e utilizações destes no tratamento de distúrbios genéticos
JP2010501571A (ja) 2006-08-23 2010-01-21 ニューロジェン・コーポレーション ハロアルキル−置換ピリミジノン誘導体
EP2219646A4 (en) * 2007-12-21 2010-12-22 Univ Rochester PROCESS FOR EXTENDING THE LIFE OF EUKARYOTIC ORGANISMS
EP2422817A1 (en) 2010-07-29 2012-02-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Flavin-nucleic acid ligand conjugates
EP2600865B1 (en) * 2010-08-05 2018-11-14 Université de Lille Compound useful for the treatment of nonsense-mutation-mediated diseases and pharmaceutical composition comprising said compound
AP2015008441A0 (en) 2012-12-13 2015-05-31 Novartis Ag Pyrimido [4,5-B]quinoline-4,5(3H,10H)-diones as nonsense mutation suppressors

Also Published As

Publication number Publication date
IN2015DN03998A (h) 2015-10-02
MX2015007562A (es) 2015-10-14
MA38157A1 (fr) 2016-12-30
EA201591105A1 (ru) 2015-10-30
KR20150092306A (ko) 2015-08-12
CL2015001610A1 (es) 2015-08-07
EP2931282A1 (en) 2015-10-21
EP2931282B1 (en) 2018-10-31
US9649314B2 (en) 2017-05-16
MX363437B (es) 2019-03-22
CN104837490A (zh) 2015-08-12
CN107569487A (zh) 2018-01-12
KR101760586B1 (ko) 2017-07-21
PH12015501216A1 (en) 2015-08-17
JP6076498B2 (ja) 2017-02-08
EA028673B1 (ru) 2017-12-29
AU2013358591A1 (en) 2015-05-28
IL239244A0 (en) 2015-07-30
AU2013358591B2 (en) 2016-08-25
CN104837490B (zh) 2017-10-03
ES2709034T3 (es) 2019-04-12
BR112015013535A2 (pt) 2017-07-11
HK1209637A1 (en) 2016-04-08
PE20151062A1 (es) 2015-08-05
JP2016503003A (ja) 2016-02-01
WO2014091446A1 (en) 2014-06-19
CA2890692A1 (en) 2014-06-19
TN2015000262A1 (en) 2016-10-03
US20170266189A1 (en) 2017-09-21
CR20150314A (es) 2015-08-10
SG11201503684WA (en) 2015-06-29
CU20150061A7 (es) 2015-12-23
US20150335646A1 (en) 2015-11-26

Similar Documents

Publication Publication Date Title
IL239244A0 (en) Pyrimido[4,5-b] quinoline-5, 4 (3h,10h) - discussions as suppressors of non-sense mutations
IL240402A0 (en) Tetrahydroimidazo[d–5,1][4,1]oxazapine deriv
ZA201408843B (en) Imidazo[1,2-b]pyridazine derivative as kinase inhibitor
IL254224A0 (en) 7-substituted 5-alkyl-[4,2,1]triazolo[5,1-a]pyrimidine derivatives as pde2 inhibitors
ME03034B (me) Jedinjenja [1 ,2 ,4]triazol0[1 ,5-c]hinazol/n-5-amina supstiтuisana sa heterobiciklo pogodna za lečenje ili prevenciju poremećaja centralnog nervnog sistema
IL234485A (en) Compounds based on imidazo [2,1 – b] pyridazine
IL243092B (en) New triazolo[d–4,5]pyrimidine histories
AP2014007820A0 (en) PDE9 inhibitors with imidazo triazinone backbone
HUE045663T2 (hu) Pteridinek, mint FGFR inhibitorok
ZA201407828B (en) Bicyclic pyrazinone derivatives
HUE043108T2 (hu) (5,6-dihidro)pirimido[4,5-e]indolizinek
ZA201406323B (en) Triazolo[4,5-d]pyrimidine derivatives
EP2801439A4 (en) VERTICAL MACHINING CENTER
PT2694513E (pt) Derivados de pirazolopirimidina
EP2970278A4 (en) Pyrrolo [2,3] PYRIDINE KINASE INHIBITORS CDK9-
GB201313823D0 (en) Axisymmetrical Intermediate Case Part Including an Insert positioned in an Annular Groove
ZA201507151B (en) Antiviral indolo[2,3-b]quinoxaline
IL236808B (en) Piperazino[1,2-a]indol-1-ones and [1,4]diazepino[1,2-a]indol-1-one
GB201211756D0 (en) Novel isothiazolo [4,3-b]pyridines
GB201219129D0 (en) Triazolo(4,5-d)pyrmindine compounds
AU344103S (en) Modular outdoor seating
GB201221462D0 (en) Novel isothiazolo[5,4-b]pyridines
GB201213663D0 (en) Novel isothiazolo[5,4-b]pyridines
PH22012000559U1 (en) Multi-purpose stool